[go: up one dir, main page]

NO20091264L - Anti-myostatin antistoffer - Google Patents

Anti-myostatin antistoffer

Info

Publication number
NO20091264L
NO20091264L NO20091264A NO20091264A NO20091264L NO 20091264 L NO20091264 L NO 20091264L NO 20091264 A NO20091264 A NO 20091264A NO 20091264 A NO20091264 A NO 20091264A NO 20091264 L NO20091264 L NO 20091264L
Authority
NO
Norway
Prior art keywords
myostatin
antibodies
myostatin antibodies
increasing
gdf
Prior art date
Application number
NO20091264A
Other languages
English (en)
Inventor
Lihua Huang
Robert Owen Sayers
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20091264L publication Critical patent/NO20091264L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Monoklonale anti-myostatin antistoffer som foretrukket binder myostatin i forhold til GDF-11, har sterk bindingsaffinitet til myostatin og er resistente overfor kjemisk nedbryting. Antistoffer ifølge oppfinnelsen er anvendelige for å øke muskelmasse, øke bentetthet eller for behandling eller hindring av forskjellige forstyrrelser hos pattedyr og fuglearter.
NO20091264A 2006-09-05 2009-03-26 Anti-myostatin antistoffer NO20091264L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82449806P 2006-09-05 2006-09-05
PCT/US2007/076604 WO2008030706A2 (en) 2006-09-05 2007-08-23 Anti-myostatin antibodies

Publications (1)

Publication Number Publication Date
NO20091264L true NO20091264L (no) 2009-04-02

Family

ID=39047560

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091264A NO20091264L (no) 2006-09-05 2009-03-26 Anti-myostatin antistoffer

Country Status (21)

Country Link
US (1) US8063188B2 (no)
EP (1) EP2066695B1 (no)
JP (1) JP5058261B2 (no)
KR (1) KR101123531B1 (no)
CN (1) CN101511871B (no)
AU (1) AU2007292555B2 (no)
BR (1) BRPI0716249A2 (no)
CA (1) CA2661836A1 (no)
DK (1) DK2066695T3 (no)
EA (1) EA015916B1 (no)
ES (1) ES2404941T3 (no)
HR (1) HRP20130320T1 (no)
IL (1) IL196806A0 (no)
MX (1) MX2009002470A (no)
NO (1) NO20091264L (no)
PL (1) PL2066695T3 (no)
PT (1) PT2066695E (no)
RS (1) RS52787B (no)
SI (1) SI2066695T1 (no)
UA (1) UA98308C2 (no)
WO (1) WO2008030706A2 (no)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2533464T3 (es) 2005-10-06 2015-04-10 Eli Lilly And Company Anticuerpos anti-miostatina
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
WO2007114319A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
EP2708559B1 (en) 2008-04-11 2018-03-28 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TW201029662A (en) 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
UY33421A (es) 2010-06-03 2011-12-30 Glaxo Wellcome House Proteinas de union al antígeno humanizados
JP2013537425A (ja) 2010-08-16 2013-10-03 アムジエン・インコーポレーテツド ミオスタチンに結合するポリペプチド、組成物および方法
TWI654204B (zh) 2010-11-30 2019-03-21 中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
HUE038570T2 (hu) 2011-11-14 2018-10-29 Regeneron Pharma Készítmények és eljárások izomtömeg és izomerõ növelésére GDF8 és/vagy aktivin A specifikus antagonizálásával
FR2982860B1 (fr) 2011-11-18 2015-07-10 Ass Fr Contre Les Myopathies Utilisation de la fibromoduline et du lumican pour augmenter la masse musculaire
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
RU2729831C2 (ru) 2012-08-24 2020-08-12 Чугаи Сейяку Кабусики Кайся ВАРИАНТЫ FcγRIIB-СПЕЦИФИЧЕСКОЙ Fc-ОБЛАСТИ
PT3835310T (pt) 2012-09-13 2024-05-20 Bristol Myers Squibb Co Proteínas de domínio de estrutura à base de fibronectina que ligam à miostatina
KR20210130260A (ko) 2013-04-02 2021-10-29 추가이 세이야쿠 가부시키가이샤 Ｆｃ영역 개변체
DK2981822T3 (da) 2013-05-06 2020-12-07 Scholar Rock Inc Sammensætninger og fremgangsmåder til vækstfaktormodulation
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
US20170248609A1 (en) 2014-01-27 2017-08-31 Novartis Ag Biomarkers predictive of muscle atrophy, method and use
WO2016073853A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
SG11201703748PA (en) * 2014-11-24 2017-06-29 Somalogic Inc Nucleic acid compounds for binding growth differentiation factor 11
CA2963760A1 (en) 2014-12-19 2016-06-23 Yoshinao Ruike Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
WO2016120647A2 (en) 2015-01-30 2016-08-04 Debreceni Egyetem Muscle regeneration
MX2017008978A (es) 2015-02-05 2017-10-25 Chugai Pharmaceutical Co Ltd Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, antiocuerpor de union a interleucina 8 (il-8) y usos de los mismos.
TWI708845B (zh) * 2015-02-09 2020-11-01 美商身體邏輯股份有限公司 用於結合生長分化因數8之核酸化合物
CN107771081A (zh) 2015-04-15 2018-03-06 瑞泽恩制药公司 用gdf8抑制剂增加力量和功能的方法
HU230620B1 (hu) 2015-05-14 2017-04-28 ALU-ÖNTŐ Fémöntő és Fémmegmunkáló Ipari Eljárás vékonyfalú, tagolt, részletgazdag alumínium öntvények homokformázásos technológiával, gravitációs öntéssel történő előállítására
JP6142069B1 (ja) * 2015-12-18 2017-06-07 中外製薬株式会社 抗ミオスタチン抗体、変異Ｆｃ領域を含むポリペプチド、および使用方法
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
AU2017206069A1 (en) 2016-01-08 2018-07-19 Scholar Rock, Inc. Anti-pro/latent myostatin antibodies and methods of use thereof
TWI831965B (zh) 2016-08-05 2024-02-11 日商中外製藥股份有限公司 Il-8相關疾病之治療用或預防用組成物
GB201620119D0 (en) 2016-11-29 2017-01-11 Pharmafox Therapeutics Ag Compounds
HUE061656T2 (hu) * 2017-01-06 2023-07-28 Scholar Rock Inc Metabolikus betegségek kezelése a miosztatin aktiválás gátlásával
MA52417A (fr) 2018-03-01 2021-01-06 Regeneron Pharma Procédés de modification de composition corporelle
DK3773713T3 (da) 2018-04-06 2025-08-18 Regeneron Pharma Leptinreceptoragonistantistof til anvendelse i forøgelse af knoglemasse hos et individ, der lider af metabolisk dysfunktion eller hypoleptinæmI
US20240247071A2 (en) 2018-12-18 2024-07-25 Regeneron Pharmaceuticals, Inc. Compositions and Methods for Enhancing Body Weight and Lean Muscle Mass Using Antagonists Against Leptin Receptor, GDF8 and Activin A
KR20250075642A (ko) 2022-09-21 2025-05-28 리제너론 파아마슈티컬스, 인크. 비만, 당뇨병 및 간 기능 장애를 치료하는 방법
IL321628A (en) 2022-12-22 2025-08-01 Scholar Rock Inc Selective and potent inhibitory antibodies for myostatin activation

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021681A1 (en) 1993-03-19 1994-09-29 Johns Hopkins University School Of Medicine Growth differentiation factor-8
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
ATE343635T1 (de) 1993-05-12 2006-11-15 Genetics Inst Llc Bmp-11 zusammenstellungen
JPH10502811A (ja) 1994-07-08 1998-03-17 ザ ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 増殖分化因子−１１
US6008434A (en) 1994-07-08 1999-12-28 Johns Hopkins University School Of Medicine Growth differentiation factor-11 transgenic mice
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
AU8666398A (en) 1997-08-01 1999-02-22 Johns Hopkins University School Of Medicine, The Methods to identify growth differentiation factor (gdf) receptors
US6696260B1 (en) 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
AU1276399A (en) 1997-11-07 1999-05-31 Genetics Institute Inc. Neuronal uses of bmp-11
GB2333706A (en) 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals
AU2586199A (en) 1998-02-05 1999-08-23 Johns Hopkins University School Of Medicine, The Growth differentiation factor-8
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
US6368597B1 (en) 1998-05-06 2002-04-09 Matamorphix, Inc. Methods of treating diabetes
ATE322681T1 (de) 1999-01-21 2006-04-15 Metamorphix Inc Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
CA2496213C (en) 2002-09-16 2013-11-19 The Johns Hopkins University Metalloprotease activation of myostatin, and methods of modulating myostatin activity
AR047392A1 (es) * 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
PL383616A1 (pl) 2002-12-20 2008-04-14 Amgen Inc. Środki wiążące inhibitujące miostatynę
RU2322261C2 (ru) 2003-06-02 2008-04-20 Уайт Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
AR046833A1 (es) 2003-11-10 2005-12-28 Schering Corp Anticuerpos anti-interleuquina-10
NZ529860A (en) 2003-11-28 2006-10-27 Ovita Ltd Muscle growth regulator mighty and use in promoting muscle mass and treating muscle wasting diseases
CN1902221A (zh) 2003-12-31 2007-01-24 先灵-普劳有限公司 基于中和表位的生长增强疫苗
EA014112B1 (ru) * 2004-03-23 2010-10-29 Эли Лилли Энд Компани Моноклональное антитело к миостатину и способы его применения
CA2575563A1 (en) 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
US20060216279A1 (en) 2005-03-22 2006-09-28 Glass David J Myostatin inhibiting fusion polypeptides and therapeutic methods thereof
BRPI0609449A2 (pt) 2005-03-23 2010-04-06 Wyeth Corp detecção de agentes de modulação de gdf-8
ZA200709291B (en) 2005-04-25 2009-01-28 Pfizer Antibodies to myostatin
WO2006128190A2 (en) 2005-05-27 2006-11-30 The Regents Of The University Of California Compositions and methods for treatment of neural disorders using transforming growth factor-beta superfamily proteins and their antagonists
ES2659114T3 (es) 2005-08-19 2018-03-13 Wyeth Llc Anticuerpos antagonistas contra GDF-8 y usos en el tratamiento de ALS y otros trastornos asociados con GDF-8
ES2533464T3 (es) * 2005-10-06 2015-04-10 Eli Lilly And Company Anticuerpos anti-miostatina
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
US20070149458A1 (en) 2005-12-06 2007-06-28 Amgen Inc. Uses of myostatin antagonists
US20070190056A1 (en) 2006-02-07 2007-08-16 Ravi Kambadur Muscle regeneration compositions and uses therefor
TWI573802B (zh) 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途

Also Published As

Publication number Publication date
HK1133018A1 (en) 2010-03-12
PL2066695T3 (pl) 2013-08-30
MX2009002470A (es) 2009-03-20
AU2007292555A1 (en) 2008-03-13
CA2661836A1 (en) 2008-03-13
AU2007292555B2 (en) 2012-05-31
SI2066695T1 (sl) 2013-05-31
US8063188B2 (en) 2011-11-22
HRP20130320T1 (en) 2013-05-31
UA98308C2 (en) 2012-05-10
KR20090039821A (ko) 2009-04-22
RS52787B (sr) 2013-10-31
CN101511871B (zh) 2012-07-18
EA015916B1 (ru) 2011-12-30
IL196806A0 (en) 2011-08-01
JP2010502633A (ja) 2010-01-28
US20100166764A1 (en) 2010-07-01
KR101123531B1 (ko) 2012-04-20
PT2066695E (pt) 2013-05-23
BRPI0716249A2 (pt) 2013-09-03
CN101511871A (zh) 2009-08-19
EP2066695A2 (en) 2009-06-10
DK2066695T3 (da) 2013-06-10
ES2404941T3 (es) 2013-05-29
EP2066695B1 (en) 2013-03-27
WO2008030706A2 (en) 2008-03-13
WO2008030706A3 (en) 2008-05-02
JP5058261B2 (ja) 2012-10-24
EA200970251A1 (ru) 2009-08-28

Similar Documents

Publication Publication Date Title
NO20091264L (no) Anti-myostatin antistoffer
NO20082073L (no) Anti-myostatin-antistoffer
NO20082167L (no) Anti-Myostatin-antistoffer
NO20091926L (no) Anti-Notch3-agonist-antistoffer og deres anvendelse ved behandlingen av Notch3-relaterte sykdommer
MA32982B1 (fr) Proteines de liaison au recepteur cgrp humain
NO20092652L (no) Konstruert anti-TSLP-antistoff
EA202191176A1 (ru) Поливалентные модуляторы регуляторных т-клеток
EA200900403A1 (ru) Соединения, которые модулируют рецептор св2
EA201490822A1 (ru) Модифицированные полипептиды рецептора активина и их применение
EA200800759A1 (ru) Моноклональные антитела человека к киназе-1, подобной рецептору активина
EA201100523A1 (ru) Соединения сульфонила, которые селективно модулируют рецептор св2
MX2009006891A (es) Anticuerpos cd44.
EA201791742A1 (ru) Антитела, направленные против гена-3 активации лимфоцитов (lag-3)
NO20065252L (no) Behandling av forstyrrelser
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
EA200901119A1 (ru) АНТИТЕЛА ПРОТИВ ErbB3 И ИХ ПРИМЕНЕНИЕ
NO20080302L (no) Humane anti-B7RP1 noytraliserende antistoffer
EA201792184A1 (ru) Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3)
ATE538650T1 (de) Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht
EA201071126A1 (ru) Антагонисты рецепторов глюкагона
BRPI0506679A (pt) métodos de tratar osteoartrite com antagonistas de il-6
WO2007042309A3 (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
EA201100133A1 (ru) Антагонисты рецепторов простагландина d
WO2009052431A3 (en) Cd19 binding agents and uses thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application